Literature DB >> 33362767

Case Report: Secondary Hemophagocytic Lymphohistiocytosis With Disseminated Infection in Chronic Granulomatous Disease-A Serious Cause of Mortality.

Jacqueline D Squire1, Stephanie N Vazquez2, Angela Chan3, Michele E Smith4, Deepak Chellapandian5, Laura Vose6, Beatriz Teppa6, I Celine Hanson7, Ivan K Chinn7, Lisa Forbes-Satter7, Filiz O Seeborg7, Sarah K Nicholas7, Caridad A Martinez8, Carl E Allen8, Thomas J Connors4, Prakash Satwani9, Maria Shtessel3, Hanadys Ale10, Lenora M Noroski7, Nicholas L Rider7, Joshua D Milner3, Jennifer W Leiding1.   

Abstract

Chronic granulomatous disease (CGD) is a primary immune deficiency due to defects in phagocyte respiratory burst leading to severe and life-threatening infections. Patients with CGD also suffer from disorders of inflammation and immune dysregulation including colitis and granulomatous lung disease, among others. Additionally, patients with CGD may be at increased risk of systemic inflammatory disorders such as hemophagocytic lymphohistiocytosis (HLH). The presentation of HLH often overlaps with symptoms of systemic inflammatory response syndrome (SIRS) or sepsis and therefore can be difficult to identify, especially in patients with a primary immune deficiency in which incidence of infection is increased. Thorough evaluation and empiric treatment for bacterial and fungal infections is necessary as HLH in CGD is almost always secondary to infection. Simultaneous treatment of infection with anti-microbials and inflammation with immunosuppression may be needed to blunt the hyperinflammatory response in secondary HLH. Herein, we present a series of X-linked CGD patients who developed HLH secondary to or with concurrent disseminated CGD-related infection. In two patients, CGD was a known diagnosis prior to development of HLH and in the other two CGD was diagnosed as part of the evaluation for HLH. Concurrent infection and HLH were fatal in three; one case was successfully treated, ultimately receiving hematopoietic stem cell transplantation. The current literature on presentation, diagnosis, and treatment of HLH in CGD is reviewed.
Copyright © 2020 Squire, Vazquez, Chan, Smith, Chellapandian, Vose, Teppa, Hanson, Chinn, Forbes-Satter, Seeborg, Nicholas, Martinez, Allen, Connors, Satwani, Shtessel, Ale, Noroski, Rider, Milner and Leiding.

Entities:  

Keywords:  case report; chronic granulomatous disease; hemophagocytic lymphohistiocytosis; infection; inflammation; primary immune deficiency; sepsis

Year:  2020        PMID: 33362767      PMCID: PMC7756012          DOI: 10.3389/fimmu.2020.581475

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  27 in total

1.  A case of macrophage activation syndrome developing in a patient with chronic granulomatous disease-associated colitis.

Authors:  Kazuko Akagi; Toshinao Kawai; Nobuyuki Watanabe; Midori Yokoyama; Katsuhiro Arai; Shizuko Harayama; Shinji Oana; Masafumi Onodera
Journal:  J Pediatr Hematol Oncol       Date:  2014-04       Impact factor: 1.289

2.  Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections.

Authors:  Dana T Lounder; Qiong Bin; Cristina de Min; Michael B Jordan
Journal:  Blood Adv       Date:  2019-01-08

Review 3.  Hemophagocytic lymphohistiocytosis: Pathogenesis, diagnosis, and management.

Authors:  Akira Morimoto; Yozo Nakazawa; Eiichi Ishii
Journal:  Pediatr Int       Date:  2016-09       Impact factor: 1.524

Review 4.  Similar but not the same: Differential diagnosis of HLH and sepsis.

Authors:  Rafał Machowicz; Gritta Janka; Wieslaw Wiktor-Jedrzejczak
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-23       Impact factor: 6.312

Review 5.  Treatment of hemophagocytic lymphohistiocytosis.

Authors:  Yini Wang; Zhao Wang
Journal:  Curr Opin Hematol       Date:  2017-01       Impact factor: 3.284

6.  Fatal hemophagocytic lymphohistiocytosis in X-linked chronic granulomatous disease associated with a perforin gene variant.

Authors:  Joris M van Montfrans; Eva Rudd; Lisette van de Corput; Jan-Inge Henter; Peter Nikkels; Nico Wulffraat; Jaap J Boelens
Journal:  Pediatr Blood Cancer       Date:  2009-04       Impact factor: 3.167

7.  Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.

Authors:  Franco Locatelli; Michael B Jordan; Carl Allen; Simone Cesaro; Carmelo Rizzari; Anupama Rao; Barbara Degar; Timothy P Garrington; Julian Sevilla; Maria-Caterina Putti; Franca Fagioli; Martina Ahlmann; Jose-Luis Dapena Diaz; Michael Henry; Fabrizio De Benedetti; Alexei Grom; Genevieve Lapeyre; Philippe Jacqmin; Maria Ballabio; Cristina de Min
Journal:  N Engl J Med       Date:  2020-05-07       Impact factor: 91.245

Review 8.  Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis.

Authors:  Mounica Vallurupalli; Nancy Berliner
Journal:  Blood       Date:  2019-11-21       Impact factor: 22.113

Review 9.  Noninfectious Manifestations and Complications of Chronic Granulomatous Disease.

Authors:  Sarah E Henrickson; Artemio M Jongco; Kelly F Thomsen; Elizabeth K Garabedian; Isaac P Thomsen
Journal:  J Pediatric Infect Dis Soc       Date:  2018-05-09       Impact factor: 3.164

10.  Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis.

Authors:  Ivan K Chinn; Olive S Eckstein; Erin C Peckham-Gregory; Baruch R Goldberg; Lisa R Forbes; Sarah K Nicholas; Emily M Mace; Tiphanie P Vogel; Harshal A Abhyankar; Maria I Diaz; Helen E Heslop; Robert A Krance; Caridad A Martinez; Trung C Nguyen; Dalia A Bashir; Jordana R Goldman; Asbjørg Stray-Pedersen; Luis A Pedroza; M Cecilia Poli; Juan C Aldave-Becerra; Sean A McGhee; Waleed Al-Herz; Aghiad Chamdin; Zeynep H Coban-Akdemir; Shalini N Jhangiani; Donna M Muzny; Tram N Cao; Diana N Hong; Richard A Gibbs; James R Lupski; Jordan S Orange; Kenneth L McClain; Carl E Allen
Journal:  Blood       Date:  2018-04-09       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.